PULMOSTENT

Development & Evaluation of a Viable Stent Device for the Treatment of BronchoTracheal Cancer

Coordinatore	UNIVERSITAETSKLINIKUM AACHEN    more  Organization address address: Pauwelsstrasse 30 city: AACHEN postcode: 52074 contact info Nome: Volker Cognome: Legewie Email: send email Telefono: +49 241 80 88494 Fax: +49 241 80 82 057
Nazionalità Coordinatore	Germany [DE]
Totale costo	4˙085˙248 €
EC contributo	3˙167˙699 €
Programma	FP7-NMP Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies
Code Call	FP7-NMP-2011-SMALL-5
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-04-01   -   2015-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAETSKLINIKUM AACHEN  Organization address address: Pauwelsstrasse 30 city: AACHEN postcode: 52074 contact info Nome: Volker Cognome: Legewie Email: send email Telefono: +49 241 80 88494 Fax: +49 241 80 82 057	DE (AACHEN)	coordinator	710˙902.92
2	NATIONAL UNIVERSITY OF IRELAND, GALWAY  Organization address address: University Road - city: GALWAY contact info Titolo: Ms. Nome: Mari Cognome: Vahey Email: send email Telefono: +353 91 495939	IE (GALWAY)	participant	557˙980.00
3	EPITHELIX SARL  Organization address address: CHEMIN DES AULX 14 city: PLAN LES OUATES postcode: 1228 contact info Titolo: Dr. Nome: Ludovic Cognome: Wiszniewski Email: send email Telefono: +41 22 794 65 16 Fax: +41 22 794 65 17	CH (PLAN LES OUATES)	participant	419˙610.00
4	UNIVERSITEIT UTRECHT  Organization address address: Heidelberglaan 8 city: UTRECHT postcode: 3584 CS contact info Titolo: Mr. Nome: Martin Cognome: De Geest Email: send email Telefono: +31 30 253 2205	NL (UTRECHT)	participant	406˙863.00
5	RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN  Organization address address: Templergraben 55 city: AACHEN postcode: 52062 contact info Titolo: Prof. Nome: Ernst Cognome: Schmachtenberg Email: send email Telefono: +49 241 80 94000 Fax: +49 241 80 92102	DE (AACHEN)	participant	383˙074.00
6	VYSERA BIOMEDICAL LIMITED  Organization address address: BMR HOUSE PARKMORE INDUSTRIAL ESTATE city: Galway contact info Titolo: Dr. Nome: Niall Cognome: Behan Email: send email Telefono: +353 87 6614920	IE (Galway)	participant	367˙847.00
7	3T TextilTechnologieTransfer GmbH  Organization address address: OTTO-BLUMENTHAL-STRASSE 1 city: Aachen postcode: 52074 contact info Titolo: Mr. Nome: Eric Cognome: Wiemer Email: send email Telefono: +49 241 80 23432 Fax: +49 241 80 22421	DE (Aachen)	participant	184˙016.00
8	NONWOTECC MEDICAL GMBH  Organization address address: NATTERMANNALLEE 1 GEBAUDE S 19 city: KOLN postcode: 50829 contact info Nome: Jessica Cognome: Minchau Email: send email Telefono: +49 221 99224720	DE (KOLN)	participant	137˙406.08

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Lung cancer is the most common cancer in terms of both incidence and mortality, worldwide. With a median age at diagnosis of 71, lung cancer is mainly affecting the aging population. Airway stenosis is a key problem with significant morbidity and premature death. Endobronchial stenting is a proven therapy to keep the airways open. Nevertheless the currently used clinical stents have major disadvantages either by rapid re-occlusion due to tumour ingrowths (metal stents) or massive mucus retention due to the interrupted mucociliary function (coated stents). The aim of the project is to develop a viable endobronchial stent (syn. PulmoStent) for the treatment of broncho-tracheal cancer diseases. The concept is based on the combination of stent technologies with the principles of tissue engineering. The PulmoStent is a multi-layered structure providing (1) a functional respiratory epithelium on the luminal side, which allows the maintenance of the mucociliary function in the stented area, (2) an embedded micro- or nanosphere formulations, enabling the sustained, local release of tumour-specific therapeutics in combination with (3) a mechanical separating layer on the external side, enabling a local tumour suppression to avoid stent displacement and restenosis by a growing tumour. The PulmoStent is a step change beyond the state-of-the-art from a passive to a viable and functional active implant tailored to the patient. It focuses on a clearly identified clinical need for the treatment of lung cancer. The combination of different kinds of biomaterials to a co-scaffold system for the bio-functionalization of the stent will lead to an improved performance of endobronchial stents and thereby to longer durability. The novel PulmoStent will improve the quality of life and increase the life expectancy of lung cancer patients, because of the reduced mucus retention in the stented area, and herewith the reduced risk of life-threatening pneumonia and the local tumour suppression.'